← All trials
NCT05515562
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Aug 25, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wake Forest UniversityLead sponsor
- Paratek Pharmaceuticals IncCollaborator
- University of HoustonCollaborator
- Wake Forest UniversityOverall official - principal investigator
- High Point UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.